Alpha-lipoic acid (ALA) is a dithioline compound that is synthesised in the body from the octanoic acid (C8) fatty acid and that is unique among antioxidants in that it is both water-soluble and fat-soluble, allowing it to function in both aqueous and lipid compartments of the cell. This dual solubility makes ALA the central hub of the cellular antioxidant network — it can regenerate other antioxidants including vitamin C, vitamin E, glutathione, and coenzyme Q10, and it can neutralise a broad range of reactive oxygen species (ROS) and reactive nitrogen species (RNS) in every cellular compartment. ALA is also a cofactor for the pyruvate dehydrogenase (PDH) and alpha-ketoglutarate dehydrogenase (AKGDH) enzyme complexes, which are two of the most important enzymes in the TCA cycle and which are essential for the conversion of glucose to ATP through aerobic metabolism. This dual role of ALA as both an antioxidant and a metabolic cofactor makes it one of the most important and most versatile molecules in cellular energy metabolism.
The Dihydrolipoic Acid Pool and Antioxidant Regeneration
Alpha-lipoic acid exists in two forms — the oxidised form (ALA) and the reduced form (dihydrolipoic acid, DHLA), and it is the balance between these two forms that determines the antioxidant activity of the ALA pool. When ALA is in its reduced form (DHLA), it is a potent reducing agent that can regenerate vitamin C, vitamin E, glutathione, and coenzyme Q10 from their oxidised forms. When ALA is in its oxidised form (ALA), it can neutralise the hydroxyl radical, the singlet oxygen, and the hypochlorous acid, and it can chelate the transition metals (iron, copper) that are the primary catalysts of the Fenton reaction that generates the highly damaging hydroxyl radical. This dual antioxidant function of ALA/DHLA (as a direct scavenger and as a regenerator of other antioxidants) is unique in the antioxidant network and makes ALA the central antioxidant hub that coordinates the activity of all the other antioxidants in the cell.
The importance of ALA in the antioxidant network is underscored by the observation that ALA deficiency (which is rare in isolation but which can develop in conditions of general nutritional deficiency and in the mitochondrial dysfunction that characterises ageing) is associated with impaired antioxidant defence, increased oxidative stress, and the cellular dysfunction that is associated with oxidative damage in all organ systems. ALA supplementation (at 300-600mg daily of the R-enantiomer, which is the naturally occurring form) has been shown in multiple RCTs to improve insulin sensitivity in people with type 2 diabetes and metabolic syndrome, to reduce neuropathic pain in people with diabetic neuropathy, and to reduce the markers of oxidative stress in people with chronic inflammatory conditions.
Alpha-Lipoic Acid and Insulin Sensitivity
The effect of ALA on insulin sensitivity is one of the most clinically significant and most consistent effects of this supplement. Multiple RCTs have demonstrated that ALA supplementation at 300-600mg daily for 8-12 weeks significantly improves insulin sensitivity (as measured by the hyperinsulinaemic-euglycaemic clamp, the gold standard for measuring insulin sensitivity) in people with type 2 diabetes and with the metabolic syndrome. The mechanism of this insulin-sensitising effect is thought to involve the ALA-induced activation of the AMP-activated protein kinase (AMPK) pathway (which is the primary cellular energy sensor and which regulates glucose uptake and fatty acid oxidation), the ALA-induced reduction in oxidative stress (which interferes with the insulin signalling pathway at multiple points), and the ALA-induced improvement in mitochondrial function (which is impaired in the insulin resistance that characterises type 2 diabetes). A meta-analysis of 12 RCTs found that ALA supplementation significantly reduced fasting blood glucose, fasting insulin, and HbA1c in people with type 2 diabetes, with an effect size that is comparable to that of the metformin.
Practical Application
For general alpha-lipoic acid supplementation, the evidence-based dose is 300-600mg of R-alpha-lipoic acid daily (taken in divided doses, preferably before meals for optimal absorption). The R-enantiomer is preferred over the synthetic S-enantiomer because it is the naturally occurring form and has better bioavailability. ALA is generally well-tolerated with no significant adverse effects at therapeutic doses, though very high doses (above 1,200mg daily) can produce mild GI upset and a temporary body odour. For comprehensive antioxidant support, ALA pairs well with vitamin C (which ALA regenerates from its oxidised form, forming a regenerative antioxidant cycle), with vitamin E (which ALA regenerates from its oxidised form, forming the regenerative antioxidant cycle that is most important for the lipid compartment), with selenium (which is required for the glutathione peroxidase enzymes that work alongside ALA in the antioxidant defence system), with the omega-3 fatty acids (which have anti-inflammatory effects and which support mitochondrial membrane composition), and with the B-complex vitamins (which are required for the function of the PDH and AKGDH enzyme complexes for which ALA is a cofactor).
Leave a Reply